IND 2 Results Uses Nextrials' New Database Design Tools for Prism(R) to Launch Faster and More Economical Phase I Clinical Trials
IND 2 Results Helps Sponsors Control Costs Through Significant Reductions in Study Start Timeframes
(firmenpresse) - SAN RAMON, CA -- (Marketwire) -- 09/12/11 -- . (), a leader in clinical research software and services, today announced that its new Prism® database design tools have been shown to significantly lower costs and to reduce clinical trial start times by as much as 50 percent. Atlanta-based (I2R), a contract research organization offering drug development consultation and clinical trial management services, not only found that the Prism design tools helped shorten the time to build a database, they also facilitated subsequent validation and documentation.
"This is especially good news for Phase I and small study sponsors, particularly those looking to maximize their limited financial resources," noted Amy Morris, CEO of I2R. "Prism's design tools provide access to a cost-effective electronic data capture system that delivers real-time data to companies and facilitates much faster decision making around drug safety, dose strengths and, ultimately, efficacy."
Nextrials integrated Prism with 's industry-leading Origin™ products so that users could easily build customized clinical trial databases in just a few mouse clicks. The built-in design tools include automatically generated database specifications and submission-ready CRFs that can be compiled to create large libraries of forms. Sponsors and CROs such as I2R can then utilize the library from study to study, reducing design and start times so that clinical trials can be initiated in a matter of days instead of weeks or months.
This week, Nextrials is showcasing Prism at the , being held September 11-14 in Baltimore, MD. Visitors can see a demonstration of Prism in the Nextrials' booth (Booth #315).
Nextrials' award-winning Prism melds sophisticated clinical trial management functionality with EDC in a single, integrated package. By receiving a constant flow of data, Prism enables sponsors and sites to fully utilize real-time integration of disparate information and data sources, such as a hospital's EHR or patient records, to better provide a continuum of care for patients enrolled in clinical trials.
An Atlanta, GA-based specialized contract research organization offering drug development consultation and clinical trial management services, IND 2 Results (I2R) envisions a different drug development paradigm -- one where biopharma companies have access to experienced development personnel and state of the art technologies that produce results while saving time and money. To accomplish this, I2R takes advantage of new technologies that enable it to streamline the development process, whether working through electronic project management rooms or submitting electronic documents. For more information, visit or call 404-867-1741.
Founded by pharmaceutical researchers in 1999, Nextrials offers today's most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,500 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit or call 925-355-3000.
Contact:
Rachel V. Berry
VOXUS, Inc.
253-444-5441
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.09.2011 - 12:00 Uhr
Sprache: Deutsch
News-ID 64678
Anzahl Zeichen: 0
contact information:
Town:
SAN RAMON, CA
Kategorie:
Software
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"IND 2 Results Uses Nextrials' New Database Design Tools for Prism(R) to Launch Faster and More Economical Phase I Clinical Trials"
steht unter der journalistisch-redaktionellen Verantwortung von
Nextrials, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
